Triple-Negative Breast Cancer Clinicopathology: A Single-Center Experience

Dedy Hermansyah, Yolanda Rahayu, Arjumardi Azrah, Gracia Pricilia, Sufida Sufida, Denny Rifsal, Albiner Simarmata


Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that does not have estrogen receptors, progesterone receptors, and HER-2 receptors. This subtype is found in 15-20% of all types of breast cancer, and it is often associated with a high recurrence rate and mortality after getting definitive therapy. The aim of our study is to investigate the clinicopathology of breast cancer in our center, where the majority were Bataknese.

Methods: We evaluated the clinical and pathological characteristics of TNBC retrospectively from medical records data, from January 2017 to December 2019 with a total of 105 patients but only 79 patients had complete clinicopathological and immunohistochemistry data. This study was conducted in Murni Teguh Memorial Hospital, Medan, Indonesia.

Results: From 79 TNBC patients, the average age at clinical presentation was 41-50 years group about 35 samples (44.3%). All patients had an invasive type of ductal carcinoma (100%). The majority of tumor size was T2 in 51 patients (64,6%), 83.6% grade 3 tumors. Both angioinvasion and lymph invasion were found in 48 patients (60.8%) while tumor-infiltrating lymphocyte (TIL) was found in 58 patients (73.4%), and 44 patients (55.7%) had lymph node metastases.

Conclusions: According to some existing literature, TNBC showed more aggressive characteristics which are the same as our study. TNBC was diagnosed at young age, grade 3 tumors, having TIL which is very likely to occur distant metastases to lymph nodes.


clinicopathology, triple-negative breast cancer


Rayson D, Payne JI, Michael JC, et al. The impact of detection method and age on survival outcomes in triple-negative breast cancer: a population based cohort analysis. Clin Breast Cancer. 2018;18(5):e955-e960.

Gowry MR, Pooja KS, Radha RP. Clinicopathological features of triple negative breast carcinoma. J Clin Diagn Res. 2017;11(1):EC05–EC08.

Radosa CJ, Eaton A, Stempel M, et al. Evaluation of local and distant recurrence patterns in patients with triple-negative breast cancer according to age. Ann Surg Oncol. 2017;24(3):698-704.

Jeanny K, Keun-Yong E, Tae RK, et al. A prognostic model for patients with triple-negative breast cancer: importance of the modified nottingham prognostic index and age. J Breast Cancer. 2017;20(1):65-73.

Abdul Aziz AA, Md Salleh MS, Ankathil R. Clinicopathological and prognostic characteristics of Malaysian triple negative breast cancer patients undergoing TAC chemotherapy regimen. Int J Breast Cancer. 2020;2020:8424365.

Aishwarya K, Antoinette MS, Lisa EP, et al. Breast cancer Incidence and mortality by molecular subtype: statewide age and racial/ethnic disparities in New Jersey. Cancer Health Disparities. 2019;3:e1–e17.

Gulbahce HE, Bernard PS, Weltzien EK, et al. Differences in molecular features of triple negative breast cancers based on age at diagnosis. Cancer. 2018;124(24):4676–84.

Medina MA, Oza G, Sharma A, et al. Triple-negative breast cancer: a review of conventional and advanced therapeutic strategies. Int J Environ Res Public Health. 2020;17(6):2078.

Widodo I, Dwianingsih EK, Aryandono T, Soeripto S. Clinicopathological characteristic and prognostic significance of Indonesian triple negative breast cancer. Indones Biomed J. 2019;11(3):225-337.

Nurwenda S, Dewayani BM, Afiati A, Hernowo BS. Ekspresi negatif melanoma cell adhesion molecule (mcam) berkorelasi dengan metastasis kelenjar getah bening aksila pada triple negative breast cancer. Indones J Clin Pharm. 2016;5(3).

DiNome M, Javier IJ, Matsuba C, et al. Clinicopathological features of triple-negative breast cancer epigenetic subtypes. Ann Surg Oncol. 2019;26(10):3344–53.

Wahba HA, El-Hadaad HA. Current approaches in treatment of triplenegative breast cancer. Cancer Biol Med. 2015;12:106-16.

Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6): e0157368.

Rui J, Xiaochi H, Jingtao L. Clinical characteristics and prognostic analysis of ipsilateral supraclavicular lymph node metastases in breast cancer patients: a retrospective study. Int J Clin Exp Pathol. 2019;12(9):3526-34.

Dewi C, Sulastri H, Fantoni J, Hafy Z. Hubungan ekpresi e-cadherin dengan invasi limfovaskular dan status KGB pada karsinoma payudara tripel negatif. Patologi. 2013; 22(1):10-16.

Hwang SY, Park, S, Kwon, Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019;199:30-57.

Walsh EM, Keane MM, Wink DA, et al. A review of triple negative breast cancer (TNBC) and the impact of inducible nitric oxide synthase on TNBC tumour biology and patient outcomes. Crit Rev Oncog. 2016;21(5-6):333-51.

Li X, Yang J, Peng L, et al. Triplenegative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161:279-87.

Full Text: PDF

DOI: 10.33371/ijoc.v15i3.791

Article Metrics

Abstract view : 147 times
PDF - 75 times


  • There are currently no refbacks.

Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.